Opko Health is a multinational biopharmaceutical and diagnostics company that seeks to establish industry leading positions in large, rapidly growing markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies. The company was founded in 2005 and is based in Miami, Florida.
GeneDx, Inc., a wholly owned subsidiary of BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today launched several new genetic tests, including repeat expansion analysis for spinocerebellar ataxia (SCA), Friedreich ataxia, and other common forms of hereditary ataxias. With these additions, GeneDx has created a comprehensive and affordable offering that covers the vast majority of genes involved with pediatric-onset and adult-onset ataxias.
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today announced COVID-19 testing agreements for players and officials, as well as team and league staff for the 2020-2021 seasons for the National Basketball Association (NBA) and National Hockey League (NHL).
Opko Health (OPK) expects to beat its previously issued guidance for PCR tests for Covid-19 for 4Q and confirmed its revenue guidance, CFO Adam Logal said earlier at the JPMorgan Healthcare conference.Logal said Opko was profitable in 3Q and also guided for profitability in 4Q and expects a full year...